To explore the therapeutic effect and risk factors of rebleeding in the treatment of liver cirrhosis complicated with esophageal and gastric variceal bleeding with enhanced nutritional support and octreotide.

A total of 112 patients with cirrhosis combined with esophageal and gastric variceal bleeding admitted to Wuxi People′s Hospital from January 2020 to June 2023 were selected.After excluding patients with incomplete data or unwillingness to participate in the study, a total of 90 patients were included.All patients underwent enhanced nutritional support assisted octreotide therapy, and clinical efficacy was observed.The nutritional status of all patients before and after treatment was compared, including triceps skinfold thickness(TSF), arm circumference(AC), and body mass index(BMI). The patients were divided into an observation group(25 cases, rebleeding after treatment)and a control group(65 cases, no bleeding after treatment)based on whether there was rebleeding after treatment.The clinical data of the two groups were Compare, and the independent risk factors of rebleeding in patients with liver cirrhosis combined with esophageal and gastric variceal bleeding after enhanced nutritional support and octreotide treatment were analyzed using univariate and multivariate logistic analysis.

After treatment, all 90 patients did not experience active bleeding, and the success rate of treatment was 100.00%.After treatment, there were 25 cases of rebleeding and 65 cases of no bleeding, with a recurrence rate of 27.78%.The TSF levels of all patients after treatment were lower than before treatment, while the AC and BMI levels were higher than before treatment(P<0.05). The results of univariate logistic analysis showed that age≥65 years, portal vein diameter, Child-Pugh score, blood sodium, and albumin concentration were risk factors for postoperative rebleeding in patients with liver cirrhosis complicated with esophageal and gastric variceal bleeding(P<0.05). The results of multivariate logistic regression analysis showed that age≥65 years, portal vein diameter, Child-Pugh score, blood sodium, and albumin concentration were all independent risk factors for rebleeding in patients with liver cirrhosis complicated with esophageal and gastric variceal bleeding after treatment(OR=6.556, 3.404, 0.598, 1.320, 2.028, P=0.001, 0.000, 0.000, 0.002, 0.000, 95% CI: 3.124-6.335, 1.381-2.358, 3.252-8.612, 1.513-2.192, all P<0.05).

Enhanced nutritional support combined with octreotide is effective in the treatment of esophageal and gastric variceal bleeding in patients with liver cirrhosis.Age≥65 years old, portal vein diameter, Child-Pugh score, blood sodium, and albumin concentration are all risk factors for rebleeding after treatment.Clinicians should pay attention to these factors during treatment and actively control disease progression to reduce the risk of rebleeding after treatment.